Skip to content
Tagged COVID-19 Biotechnology SARS-CoV-2 Life Science cancer CORONAVIRUS pandemic
BioXone

BioXone

rethinking future

March 7, 2026
  • About
  • BiotechTodayNews
    • IndiaWeekly Biotech News of India
    • WorldWeekly Biotech News of The World
  • DNA-TalesArticles
    • BiotechnopediaInteresting articles written by BioXone members and associates.
    • Scientists’ CornerArticles from the pioneers of Biotechnology.
    • Cellular CommunicationInterview of greatest researchers’ in the field.
  • Myth-LysisFact Check
  • Signalling PathwayCareer related updates
    • ExaminationsExamination related articles.
    • Job and InternshipJobs and Internship related articles.
  • Courses
  • Contact

Most Viewed This Week

October 17, 2023October 16, 2023

The Corrosion Prediction from the Corrosion Product Performance

1
October 1, 2023September 30, 2023

Nitrogen Resilience in Waterlogged Soybean plants

2
September 28, 2023September 28, 2023

Cell Senescence in Type II Diabetes: Therapeutic Potential

3
September 26, 2023September 25, 2023

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

4
September 25, 2023September 25, 2023

AI Literacy in Early Childhood Education: Challenges and Opportunities

5
September 22, 2023October 1, 2023

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

6

Search Field

Subscribe Now

  • Home
  • BiotechToday
  • COVID-19 vaccine for children: Pfizer shows progress!

Oversleeping : A Serious Health Concern

SISCAPA-based approach to detect SARS-CoV-2: What is it?

COVID-19 vaccine for children: Pfizer shows progress!
  • BiotechToday
  • World

COVID-19 vaccine for children: Pfizer shows progress!

BioTech Today November 22, 2021November 22, 2021

Ananya Ghosal, MAKAUT(WB)

COVID-19 vaccine is still a dream for children under 12. Although children are not at risk of COVID-19 like adults, their reports are still positive. The delta variant and reopening of schools combined and resulted in a keen rise in pediatric COVID-19 cases that is related to the records in the pandemic. Since the beginning of the pandemic, nearly 6.2 million children have had positive results for COVID-19. Six weeks before October 14th nearly 1.1 million children tested positive. Between January and September, nearly 280 children under the age group of 18 or above died due to COVID-19.

The eagerness of parents, children, and teachers for the reopening of school and students going back to classrooms will affect the infection growth. Vaccination of the children would result in reducing the number of disrupting years in school and reducing the spread of the virus. According to the report Kaiser Family Foundation, the survey provided the data of 34% of parents said they will vaccinate their children of age group 5-11 years as soon as their age group is eligible. In the second set of parents, 32% said that they will wait and watch the effectiveness of the vaccine before vaccinating their child, and the last set of parents, 24% said they will never vaccinate their children.

More authorization on the new perspective, some parents will be glad for adding COVID-19 vaccine in the schedule of vaccination as recent Food and Drug Administration (FDA) review has claimed that the vaccination is effective and safe for children. Some vaccines like Pfizer and BioNTech are manufacturing the vaccine that is authorized for the children under 18 years of age and for the age group of 2-5 the clinical trials are performed. There is a separate trial for the six months children.

The recent work on Vaccines

 According to the recent reports, Pfizer declares that they have submitted all of their data regarding their phase 2 and phase 3 trials of their COVID-19 vaccine for children aged between 5-11 years to the Food and Drug Administration (FDA). In immediate future, Pfizer expects authorization for immediate use of the COVID-19 vaccine as the formal submission has been done to ask for the Emergency Use Authorization (EUA) in the children of age group 5-11 years. The FDA will examine the data submitted by Pfizer for final decision. Dr. Gregory Poland is an infectious disease expert and he is also the head of Mayo Clinic’s Vaccine research group. He said about the emergency use authorization approval of COVID-19 vaccine for children of age group 5-11 years old before the end of October or Halloween.

The children or 12 years or above previously have the emergency use authorization of the vaccine. A dose of Pfizer vaccine that was adults got a dose of 30 micrograms and for children, the dose is 10 micrograms that are one-third of the dose of the adults. Just like any other COVID-19 vaccine, Pfizer also has a series of two doses, and the effectiveness will increase after 14 days of the second dose.

Dr. Poland also added that antibody responses are not shocking at all, as the doses are much lower but the generation of antibody responses are equal to the people in the age group of 12-18 years old. The kids of the age group of 6 months-4 years will get only one-tenth of the adult dose and the researchers are still working on it. In the case of adults, the doses are 30 micrograms so one-tenth of that is 3 micrograms.

 Safety protocols

 Dr. Poland stated that apart from COVID-19 vaccination other safety protocols are also important that reduce the risk of any respiratory infections and COVID-19. Some of the safety protocols that should be followed are-

  • Wearing masks in a social gathering.
  • Maintaining good hand sanitization.
  • Quarantine yourself in case you are not feeling well.

Also read: STRAUMA activation: Evaluation of stroke and trauma simultaneously

Reference

  1. Ioanes, Ellen. ‘Pfizer’s Clinical Data Puts the US One Step Closer to a Covid-19 Vaccine for Younger Kids’. Vox, 23 Oct. 2021, https://www.vox.com/2021/10/23/22741702/covid-19-pfizer-vaccine-young-children-5-to-11.
  2. Balzer, Deb, and Mayo Clinic News Network. COVID-19 Vaccine for Younger Kids a Step Closer. https://medicalxpress.com/news/2021-10-covid-vaccine-younger-kids-closer.html. Accessed 28 Oct. 2021.
  • The Corrosion Prediction from the Corrosion Product Performance
  • Nitrogen Resilience in Waterlogged Soybean plants
  • Cell Senescence in Type II Diabetes: Therapeutic Potential
  • Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP
  • AI Literacy in Early Childhood Education: Challenges and Opportunities

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Related

Tagged BioNtech children clinical trials COVID-19 delta variant Emergency Use Authorization EUA FDA Food and Drug Administration pandemic pediatric COVID-19 Pfizer positive report VACCINE

One thought on “COVID-19 vaccine for children: Pfizer shows progress!”

  1. Pingback: Sponges provide insights into nervous system evolution! - BioXone

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Next Post
  • BiotechToday
  • World

SISCAPA-based approach to detect SARS-CoV-2: What is it?

BioTech Today November 22, 2021

Sumedha B S, Bangalore University The novel human coronavirus, SARS-CoV-2 has created a global disease burden infecting>100 million humans in just over a year. It has become a major challenge to the health system worldwide. Detection is very crucial in this pandemic. Studies have shown that early detection is very necessary for disease control. Currently, […]

SISCAPA

Related Post

  • BiotechToday
  • World

Is Scar Tissue A Protective Immune Cell?

bioxone March 12, 2021March 12, 2021

Souradip Mallick, National Institute of Technology, Rourkela  Nowadays abdominal surgery is very common and many patients undergo this operation to remove internal scar tissue. This scar is the accumulation of the macrophage which is a protective immune cell. But there are many postsurgical complications. Lysis of adhesions destroys the scar tissue resulting in abdominal and […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

Scientists unravel the inner workings of DNA Repair Enzymes

bioxone October 15, 2021October 17, 2021

Richa Prakash, MSc, Central University of Punjab DNA or Deoxyribonucleic Acid is a complex molecular structure containing all the genetic information inside the cells required for the development and functioning of any organism. DNA damage occurs every day by the byproducts formed during cellular metabolism and ionizing radiations. DNA damage is any change in the […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X
  • BiotechToday
  • World

A New Method For Identifying Lichens

DNA tales August 16, 2021August 16, 2021

Shenade Annie Kerketta, Amity University Kolkata A Lichen is an organism made up of two other organisms – fungus and alga/cyanobacterium. The fungus lacks chlorophyll meaning it cannot produce its food. So, it consumes organic compounds (carbohydrates, fats, and proteins). Alga/cyanobacterium, on the other hand, does include chlorophyll thereby, producing its food. Now, some species of the […]

Share this:

  • Share on Facebook (Opens in new window) Facebook
  • Share on X (Opens in new window) X

Breaking News

The Corrosion Prediction from the Corrosion Product Performance

Nitrogen Resilience in Waterlogged Soybean plants

Cell Senescence in Type II Diabetes: Therapeutic Potential

Transgene-Free Canker-Resistant Citrus sinensis with Cas12/RNP

AI Literacy in Early Childhood Education: Challenges and Opportunities

Sustainable Methanol Vapor Sensor Made with Molecularly Imprinted Polymer

Exogenous Klotho as a Cognition Booster in Aging Primates

Terms and Conditions
Shipping and Delivery Policy
Cancellation and Refund Policy
Contact Us
Privacy Policy